An Italian study by Bologna et al. reported that, combined with the albumin–bilirubin score, immune-inflammation indicators could help identify the occurrence or recurrence of HCC in patients after DAA treatment (31). This evidence concerns the gene ALB and hepatocellular carcinoma.